ASX:AVR Anteris Technologies (AVR) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free AVR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.45%Price TargetN/A Stock AnalysisStock Analysis Get Anteris Technologies alerts: Email Address Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Anteris Technologies Stock (ASX:AVR)Anteris Technologies Ltd, a structural heart company, designs, develops, and commercializes medical devices. The company manufactures and sells ADAPT, a regenerative tissue product. Its lead product is the DurAVRTM, a transcatheter heart valve for the treatment of aortic stenosis. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.Read More Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. AVR Stock News HeadlinesApril 12, 2024 | finance.yahoo.comThose who invested in Anteris Technologies (ASX:AVR) five years ago are up 292%March 6, 2024 | msn.comASX 200 recoups early losses as major banks push higher, tech stocks pull backMarch 6, 2024 | wsj.comAnteris Technologies Ltd.March 2, 2024 | afr.comAnteris Technologies LtdFebruary 29, 2024 | finance.yahoo.comAnteris Technologies Full Year 2023 Earnings: Misses ExpectationsFebruary 8, 2024 | finance.yahoo.comAnteris Technologies Ltd's (ASX:AVR) largest shareholders are retail investors with 50% ownership, institutions own 29%January 20, 2024 | finance.yahoo.comAnteris Technologies Ltd (AVR.XA)December 19, 2023 | msn.comFDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases marketNovember 29, 2023 | proactiveinvestors.com.auFDA approval for BiVACOR's artificial heart study paves further paths for heart tech innovationNovember 21, 2023 | morningstar.comAnteris Technologies Ltd AVRNovember 21, 2023 | proactiveinvestors.com.auFIVE at FIVE AU: Mining lifts ASX; RBA minutes suggest further rate hikesNovember 20, 2023 | proactiveinvestors.com.auAnteris Technologies fields "excellent" 30-day haemodynamic...Anteris Technologies fields "excellent" 30-day haemodynamic...November 20, 2023 | proactiveinvestors.comAnteris Technologies fields "excellent" 30-day haemodynamic...October 30, 2023 | proactiveinvestors.comAnteris talks market superiority of its biomimetic TAVR valveOctober 17, 2023 | proactiveinvestors.comAnteris Technologies completes DurAVRTM Early Feasibility Study enrolmentOctober 12, 2023 | proactiveinvestors.com.auFIVE at FIVE AU: ASX slips and US markets stumble on higher-than-expected CPISeptember 12, 2023 | au.investing.comAnteris Technologies to present latest clinical data for DurAVR™September 12, 2023 | finance.yahoo.comAnteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023August 14, 2023 | businesswire.comDurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve CaseAugust 9, 2023 | finance.yahoo.comAnteris Technologies Commences US Early Feasibility StudyAugust 9, 2023 | finance.yahoo.comAnteris Technologies Commences American Depository Receipt ProgramAugust 1, 2023 | proactiveinvestors.com.auAnteris welcomes successful DurAVR valve-in-valve procedureJuly 31, 2023 | finance.yahoo.comAnteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve ProcedureJuly 30, 2023 | au.investing.comAnteris Technologies’ DurAVR heart valve used in life-saving valve-in-valve procedureJune 14, 2023 | finance.yahoo.comAnteris Technologies says latest first-in-human DurAVR™ results are next-levelSee More Headlines Receive AVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anteris Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:AVR CUSIPN/A CIKN/A Webwww.anteristech.com Phone61 1300 550 310FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($4.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-329.00% Return on Assets-127.62% Debt Debt-to-Equity Ratio8.14 Current Ratio2.60 Quick Ratio4.07 Sales & Book Value Annual Sales$4.11 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$1.61 per share Price / BookN/AMiscellaneous Outstanding Shares19,220,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.77 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Wayne G. Paterson (Age 57)CEO, MD & Executive Director Comp: $1.93MMr. Matthew McDonnellChief Financial OfficerMr. David St. DenisChief Operating OfficerDejan TorackiCorporate Development DirectorDr. Chris Meduri M.D.M.P.H., Chief Medical Officer & Member of Medical Advisory BoardMr. Stephen DenaroIndependent Non-Executive Director & Company SecretaryMore ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersJohn SeabergSold 20,000 sharesTotal: $458,800.00 ($22.94/share)Wenyi GuSold 80,500 sharesTotal: $1.63 M ($20.30/share) This page (ASX:AVR) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anteris Technologies Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Anteris Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.